Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease

Zsuzsanna Hracská, M. Baranyi, Cecilia Csölle, Flóra Gölöncsér, E. Madarász, A. Kittel, B. Sperlágh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Previous studies indicate a role of P2X7receptors in processes that lead to neuronal death. The main objective of our study was to examine whether genetic deletion or pharmacological blockade of P2X 7receptors influenced dopaminergic cell death in various models of Parkinson's disease (PD). Results: mRNA encoding P2X7and P2X 4receptors was up-regulated after treatment of PC12 cells with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). P2X7antagonists protected against MPTP and rotenone induced toxicity in the LDH assay, but failed to protect after rotenone treatment in the MTT assay in PC12 cells and in primary midbrain culture. In vivo MPTP and in vitro rotenone pretreatments increased the mRNA expression of P2X7receptors in the striatum and substantia nigra of wild-type mice. Basal mRNA expression of P2X 4receptors was higher in P2X7knockout mice and was further up-regulated by MPTP treatment. Genetic deletion or pharmacological inhibition of P2X7receptors did not change survival rate or depletion of striatal endogenous dopamine (DA) content after in vivo MPTP or in vitro rotenone treatment. However, depletion of norepinephrine was significant after MPTP treatment only in P2X7knockout mice. The basal ATP content was higher in the substantia nigra of wild-type mice, but the ADP level was lower. Rotenone treatment elicited a similar reduction in ATP content in the substantia nigra of both genotypes, whereas reduction of ATP was more pronounced after rotenone treatment in striatal slices of P2X7deficient mice. Although the endogenous amino acid content remained unchanged, the level of the endocannabinoid, 2-AG, was elevated by rotenone in the striatum of wild-type mice, an effect that was absent in mice deficient in P2X7receptors. Conclusions: We conclude that P2X7receptor deficiency or inhibition does not support the survival of dopaminergic neurons in an in vivo or in vitro models of PD.

Original languageEnglish
Article number28
JournalMolecular Neurodegeneration
Volume6
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Purinergic P2X7 Receptors
Rotenone
Parkinson Disease
Animal Models
Substantia Nigra
Corpus Striatum
Adenosine Triphosphate
PC12 Cells
Messenger RNA
Pharmacology
Endocannabinoids
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Dopaminergic Neurons
Mesencephalon
Neuroprotection
Adenosine Diphosphate
Dopamine
Norepinephrine
Cell Death
Genotype

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Clinical Neurology
  • Molecular Biology

Cite this

Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease. / Hracská, Zsuzsanna; Baranyi, M.; Csölle, Cecilia; Gölöncsér, Flóra; Madarász, E.; Kittel, A.; Sperlágh, B.

In: Molecular Neurodegeneration, Vol. 6, No. 1, 28, 2011.

Research output: Contribution to journalArticle

@article{cf8aee9931ff464ea707ec509d53893f,
title = "Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease",
abstract = "Background: Previous studies indicate a role of P2X7receptors in processes that lead to neuronal death. The main objective of our study was to examine whether genetic deletion or pharmacological blockade of P2X 7receptors influenced dopaminergic cell death in various models of Parkinson's disease (PD). Results: mRNA encoding P2X7and P2X 4receptors was up-regulated after treatment of PC12 cells with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). P2X7antagonists protected against MPTP and rotenone induced toxicity in the LDH assay, but failed to protect after rotenone treatment in the MTT assay in PC12 cells and in primary midbrain culture. In vivo MPTP and in vitro rotenone pretreatments increased the mRNA expression of P2X7receptors in the striatum and substantia nigra of wild-type mice. Basal mRNA expression of P2X 4receptors was higher in P2X7knockout mice and was further up-regulated by MPTP treatment. Genetic deletion or pharmacological inhibition of P2X7receptors did not change survival rate or depletion of striatal endogenous dopamine (DA) content after in vivo MPTP or in vitro rotenone treatment. However, depletion of norepinephrine was significant after MPTP treatment only in P2X7knockout mice. The basal ATP content was higher in the substantia nigra of wild-type mice, but the ADP level was lower. Rotenone treatment elicited a similar reduction in ATP content in the substantia nigra of both genotypes, whereas reduction of ATP was more pronounced after rotenone treatment in striatal slices of P2X7deficient mice. Although the endogenous amino acid content remained unchanged, the level of the endocannabinoid, 2-AG, was elevated by rotenone in the striatum of wild-type mice, an effect that was absent in mice deficient in P2X7receptors. Conclusions: We conclude that P2X7receptor deficiency or inhibition does not support the survival of dopaminergic neurons in an in vivo or in vitro models of PD.",
author = "Zsuzsanna Hracsk{\'a} and M. Baranyi and Cecilia Cs{\"o}lle and Fl{\'o}ra G{\"o}l{\"o}ncs{\'e}r and E. Madar{\'a}sz and A. Kittel and B. Sperl{\'a}gh",
year = "2011",
doi = "10.1186/1750-1326-6-28",
language = "English",
volume = "6",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease

AU - Hracská, Zsuzsanna

AU - Baranyi, M.

AU - Csölle, Cecilia

AU - Gölöncsér, Flóra

AU - Madarász, E.

AU - Kittel, A.

AU - Sperlágh, B.

PY - 2011

Y1 - 2011

N2 - Background: Previous studies indicate a role of P2X7receptors in processes that lead to neuronal death. The main objective of our study was to examine whether genetic deletion or pharmacological blockade of P2X 7receptors influenced dopaminergic cell death in various models of Parkinson's disease (PD). Results: mRNA encoding P2X7and P2X 4receptors was up-regulated after treatment of PC12 cells with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). P2X7antagonists protected against MPTP and rotenone induced toxicity in the LDH assay, but failed to protect after rotenone treatment in the MTT assay in PC12 cells and in primary midbrain culture. In vivo MPTP and in vitro rotenone pretreatments increased the mRNA expression of P2X7receptors in the striatum and substantia nigra of wild-type mice. Basal mRNA expression of P2X 4receptors was higher in P2X7knockout mice and was further up-regulated by MPTP treatment. Genetic deletion or pharmacological inhibition of P2X7receptors did not change survival rate or depletion of striatal endogenous dopamine (DA) content after in vivo MPTP or in vitro rotenone treatment. However, depletion of norepinephrine was significant after MPTP treatment only in P2X7knockout mice. The basal ATP content was higher in the substantia nigra of wild-type mice, but the ADP level was lower. Rotenone treatment elicited a similar reduction in ATP content in the substantia nigra of both genotypes, whereas reduction of ATP was more pronounced after rotenone treatment in striatal slices of P2X7deficient mice. Although the endogenous amino acid content remained unchanged, the level of the endocannabinoid, 2-AG, was elevated by rotenone in the striatum of wild-type mice, an effect that was absent in mice deficient in P2X7receptors. Conclusions: We conclude that P2X7receptor deficiency or inhibition does not support the survival of dopaminergic neurons in an in vivo or in vitro models of PD.

AB - Background: Previous studies indicate a role of P2X7receptors in processes that lead to neuronal death. The main objective of our study was to examine whether genetic deletion or pharmacological blockade of P2X 7receptors influenced dopaminergic cell death in various models of Parkinson's disease (PD). Results: mRNA encoding P2X7and P2X 4receptors was up-regulated after treatment of PC12 cells with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). P2X7antagonists protected against MPTP and rotenone induced toxicity in the LDH assay, but failed to protect after rotenone treatment in the MTT assay in PC12 cells and in primary midbrain culture. In vivo MPTP and in vitro rotenone pretreatments increased the mRNA expression of P2X7receptors in the striatum and substantia nigra of wild-type mice. Basal mRNA expression of P2X 4receptors was higher in P2X7knockout mice and was further up-regulated by MPTP treatment. Genetic deletion or pharmacological inhibition of P2X7receptors did not change survival rate or depletion of striatal endogenous dopamine (DA) content after in vivo MPTP or in vitro rotenone treatment. However, depletion of norepinephrine was significant after MPTP treatment only in P2X7knockout mice. The basal ATP content was higher in the substantia nigra of wild-type mice, but the ADP level was lower. Rotenone treatment elicited a similar reduction in ATP content in the substantia nigra of both genotypes, whereas reduction of ATP was more pronounced after rotenone treatment in striatal slices of P2X7deficient mice. Although the endogenous amino acid content remained unchanged, the level of the endocannabinoid, 2-AG, was elevated by rotenone in the striatum of wild-type mice, an effect that was absent in mice deficient in P2X7receptors. Conclusions: We conclude that P2X7receptor deficiency or inhibition does not support the survival of dopaminergic neurons in an in vivo or in vitro models of PD.

UR - http://www.scopus.com/inward/record.url?scp=79955512752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955512752&partnerID=8YFLogxK

U2 - 10.1186/1750-1326-6-28

DO - 10.1186/1750-1326-6-28

M3 - Article

C2 - 21542899

AN - SCOPUS:79955512752

VL - 6

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 28

ER -